In the last 6 months, three Phase 2 clinical trials for investigational drugs in dementia with Lewy bodies (DLB) have reported results. These include interim results from a small study of nilotinib, and topline results from trials of neflamapimod and CT1812 – the RewinD-LB and SHIMMER trials, respectively.
In “Clinical Trial Results: What We Learned from Recent Phase 2 Trials in DLB,” Dr. James E. Galvin, the primary study lead for the RewinD-LB and SHIMMER trials will share the results of these trials and answer your questions. Keith Fargo, Ph.D., Director of Scientific Initiatives for the Lewy Body Dementia Association, will tell you about a few planned LBD trials and how to receive more information about them.
Key Takeaways:
- Understand new potential treatments: Describe efforts to develop new therapeutics for LBD (i.e., nilotinib, neflamapimod, and/or CT1812).
- Recognize the need for Phase 3 trials: Understand that the drug development process is long and multi-stepped, so none of these drugs are likely to be available as LBD treatments for at least a few more years, if at all.
- Get involved in research: Discuss where to find information about current and upcoming trials for LBD.
James E. Galvin, M.D., M.P.H. is Professor of Neurology and Psychiatry & Behavioral Sciences, and the Alexandria and Bernard Schoninger Endowed Chair for Memory Disorders at the University of Miami Miller School of Medicine. He is Division Chief for Cognitive Neurology, Founding Director of the Comprehensive Center for Brain Health, Director and Principal Investigator of the Lewy Body Dementia Research Center of Excellence, and Principal Investigator for the Native Alzheimer’s Disease Resource Center in Minority Aging Research. Dr. Galvin has authored over 400 scientific publications (h-index=76). Dr. Galvin is principal investigator on 12 active NIH grants and has received over $120 Million in research funding from the National Institutes of Health and Private Foundations.
For questions or more information, please contact Rose Heithoff, Education Coordinator, at [email protected].
